Abstract
In chronic myeloproliferative disorders other than CML (CMPD) recurrent cytogenetic abnormalities occur, but specific patterns of chromosomal aberrations in the specific entities have so far not been detected. Thus, the value of conventional cytogenetics in the routine diagnostic setting of CMPD remains to be clarified. We performed a cytogenetic study on 409 patients with different CMPD [polycythemia vera, essential thrombocytosis (ET), idiopathic osteomyelofibrosis, chronic myelomonocytic leukemia (proliferative subtype), idiopathic hypereosinophilic syndrome (HES), myeloproliferative syndrome (unclassifiable)] and on 102 patients with suspected CMPD. Cytogenetic abnormalities occurred in different frequencies ranging from 3 to 40% depending on the subtype, and showed some specific differences with respect to their type. The highest frequency and the most complex pattern of clonal aberrations were observed in idiopathic osteomyelofibrosis. However, clonal aberrations were also found in 10% of patients with suspected CMPD establishing the diagnosis of a malignant disease. In conclusion, cytogenetics are essential in the routine diagnostic setting of CMPD or cases suspicious for CMPD. In ET and in HES the aberration rate was only 3 and 7%, respectively. Thus, cytogenetics can be omitted. However, in some of these cases molecular procedures should be integrated into the routine diagnostic process.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adewale A, Gordon D (2003) Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes. Hematol Oncol Clin North Am 17:1129–1149
Bench AJ, Cross NCP, Huntly BJP, Nacheva EP, Green AR (2001) Myeloproliferative disorders. Best Pract 14:531–551
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NCP, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214
Coutre S, Gotlib J (2004) Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Semin Cancer Biol 14:23–31
Cross NCP, Reiter A (2002) Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16:1207–1212
Goldman JM, Melo JV (2003) Mechanisms of disease—chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 349:1451–1464
Groupe Français de Cytogénétique Hématologique (1986) Cytogenetics of chronic myelomonocytic leukemia. Cancer Genet Cytogenet 21:11–30
Herishanu Y, Lishner M, Bomstein Y, Kitay-Cohen Y, Fejgin MD, Gaber E, Amiel A (2001) Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients. Cancer Genet Cytogenet 128:154–157
Jaffe E, Lee Harris, Stein H, Vardiman JW (2001) Tumours of haematopoietic and lymphoid tissues. IARC, Lyon
Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76–94
Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, Leichtle R, Green AR, Griesshammer M, Heimpel H, Pahl HL (2003) Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 102:3569–3574
Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F (1991) Karyotypic patterns in chronic myeloproliferative disorders—report on 74 cases and review of the literature. Leukemia 5:214–220
Mitelman F (1995) An International System for Human Cytogenetic Nomenclature (1995): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, October 1994
Schafer AI (2004) Current concepts—thrombocytosis. N Engl J Med 350:1211–1219
Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, Hiddemann W, Hochaus A (2003) Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 17:461–463
Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T (2002) Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 16:53–59
Sessarego M, Defferrari R, Dejana AM, Rebuttato AM, Fugazza G, Salvidio E, Ajmar F (1989) Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation—a 12-year study. Cancer Genet Cytogenet 43:57–65
Tefferi A (2000) Medical progress: myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1265
Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA (2004) Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood 103:3547–3548
Tefferi A, Meyer RG, Wyatt WA, Dewald GW (2001) Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol 115:316–319
Thiele J, Kvasnicka HM (2003) Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 82:148–152
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bacher, U., Haferlach, T., Kern, W. et al. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 84, 250–257 (2005). https://doi.org/10.1007/s00277-004-0977-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-004-0977-1